Vistagen to Participate in Upcoming Investor Conferences
Date:
Format: One-on-one meetings
Location:
Stifel 2026
Date:
Format: Fireside chat with President and CEO
Time:
Location: Virtual
The Stifel CNS presentation will be accessible via a live webcast on the “Events” page in the Investors section of Vistagen’s website and a replay will be available following the presentation.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen’s pherine pipeline currently consists of five investigational product candidates focused on improving the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause. Connect at www.Vistagen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303528278/en/
Investor Inquiries:
markmcp@vistagen.com
Media Inquiries:
mwellington@vistagen.com
Source: Vistagen